Fig. 3: Relative risk of discontinuing Anti-PCSK9 treatment. | Communications Medicine

Fig. 3: Relative risk of discontinuing Anti-PCSK9 treatment.

From: A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia

Fig. 3

This graph displays the relative risk of discontinuing anti-PCSK9 treatment over time. The x-axis represents the number of days since treatment initiation, and the y-axis displays the relative risk of discontinuing treatment. The analysis includes a total of n = 18,027 measurements in 907 persons. The shaded area around the line indicates the range within which the true relative risk is expected to fall with 95% certainty. PCSK9: proprotein convertase subtilisin/kexin type 9.

Back to article page